文献速递MDS 与骨髓增殖性肿瘤

2016年WHO诊断的纤维化前与明显原发性骨髓纤维化患者的临床表现与结局

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.
PubMed 文献 · Blood · 2017-03-28

本研究依据2016年WHO标准重新诊断661例原发性骨髓纤维化(PMF)患者,比较纤维化前/早期(pre-PMF)与明显纤维化(overt PMF)两阶段的临床与分子特征。overt PMF患者贫血、血小板减少、白细胞减少、高 blast 计数、症状、巨脾及不良核型更多,HMR突变更常见,中位生存期显著缩短(7.2年 vs 17.6年),驱动突变三阴性及HMR突变是不良结局的独立预测因素。

要点

  • overt PMF较pre-PMF中位生存期显著缩短(7.2年 vs 17.6年)。
  • 驱动突变三阴性和HMR突变是不良结局的独立预测因素。
  • overt PMF诊断时更高IPSS风险类别比例更高,随访中频率增加。

核心结论

  • 遵循2016年WHO标准可识别出PMF的两个不同患者类别,纤维化程度增加与更明显的疾病表现、不良突变谱和更差结局相关,整体提示它们可能代表一个表型连续体。

研究设计与样本

  • 对661例初诊时行骨髓活检的PMF患者按现代标准重新诊断,所有患者均有临床信息及驱动基因和选定非驱动髓系基因的体细胞突变注释。

主要发现

  • 与pre-PMF相比,overt PMF中贫血、血小板减少、白细胞减少、更高blast计数、症状、巨脾及不良核型患者更多。
  • 驱动突变类型在两组间分布相似,而HMR类别中的选定突变(ASXL1、SRSF2、IDH1/2、EZH2中任一突变)在overt PMF中更多见。
  • overt PMF诊断时处于更高国际预后评分系统风险类别的患者更多,且随访中频率增加,提示较pre-PMF有更大疾病进展倾向。
  • overt PMF中位生存期显著缩短(7.2年 vs 17.6年),驱动突变三阴性和HMR突变是不良结局的独立预测因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2016 revision of the World Health Organization (WHO) classification of myeloproliferative neoplasms defines 2 stages of primary myelofibrosis (PMF): prefibrotic/early (pre-PMF) and overt fibrotic (overt PMF) phase. In this work, we studied the clinical and molecular features of patients belonging to these categories of PMF. The diagnosis of 661 PMF patients with a bone marrow biopsy at presentation was revised according to modern criteria; clinical information and annotation of somatic mutations in both driver and selected nondriver myeloid genes were available for all patients. Compared with pre-PMF, overt PMF was enriched in patients with anemia, thrombocytopenia, leukopenia, higher blast count, symptoms, large splenomegaly, and unfavorable karyotype. The different types of driver mutations were similarly distributed between the 2 categories, whereas selected mutations comprising the high mutation risk (HMR) category (any mutations in ASXL1, SRSF2, IDH1/2, EZH2) were more represented in overt PMF. More patients with overt PMF were in higher International Prognostic Scoring System risk categories at diagnosis, and the frequency increased during follow-up, suggesting greater propensity to disease progression compared with pre-PMF. Median survival was significantly shortened in overt PMF (7.2 vs 17.6 years), with triple negativity for driver mutations and presence of HMR mutations representing independent predictors of unfavorable outcome. The findings of this "real-life" study indicate that adherence to 2016 WHO criteria allows for identification of 2 distinct categories of patients with PMF where increased grades of fibrosis are associated with more pronounced disease manifestations, adverse mutation profile, and worse outcome, overall suggesting they might represent a phenotypic continuum.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Guglielmelli P, Pacilli A, Rotunno G, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017. PMID: 28351937. doi:10.1182/blood-2017-01-761999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。